NCT04312568View on ClinicalTrials.gov

Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 10, 2018

Primary Completion Date

December 7, 2018

Study Completion Date

December 7, 2018

Conditions
Healthy Subject
Interventions
DRUG

Fadanafil

Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose

DRUG

Placebo

Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose

Trial Locations (1)

100076

Haiyan Li, Beijing

All Listed Sponsors
lead

Sihuan Pharmaceutical Holdings Group Ltd.

INDUSTRY

NCT04312568 - Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter